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1 Overview
The Sustainable East Africa Research in Community Health (SEARCH) Study is a two-phase pair-matched
cluster randomized trial, conducted in rural Kenya and Uganda. The first phase is designed to evaluate
the impact of i) annual HIV and non-communicable disease (hypertension and diabetes) population-level
testing, ii) immediate antiretroviral (ART) eligibility for all HIV-positive persons, and iii) ART, hyperten-
sion (HT) and diabetes (DM) care delivered using a streamlined patient-centered model, compared to an
active control consisting of i) baseline population-level HIV and HT/DM testing, and ii) ART and HT/DM
care delivered according to national guidelines. Inclusion and exclusion criteria as well as definition of the
control and intervention arms for Phase I are reviewed below.
This document provides the analytic plan for evaluating adult HIV incidence, health, and implemen-
tation outcomes for the first phase of the SEARCH Study, including:
• Incident HIV infection
• HIV testing uptake and coverage
• ART initiation and coverage
• Plasma HIV RNA suppression
• Mortality
• Tuberculosis
• Hypertension and diabetes control
Primary outcome analyses will be conducted after all SEARCH communities have completed three full
years of follow-up.
For all comparisons between intervention and control arms, we take a two-stage approach to our analysis.
In Stage I, we estimate the community-level outcomes defined below. In Stage II, we compare average the
community-level outcomes between intervention and control communities, accounting for the pair-matched
study design and with pre-specified adjustment for baseline factors. Primary effect estimates will be
reported on a relative scale (relative risk or rate), with variance estimates based on the estimated influence
curve, accounting for the pair-matched design, and inference based on the t-distribution with 15 degrees
of freedom [1–3]. Key analytic decisions for each outcome include the choice of candidate adjustment
variables and the weights given to each community [4]; below, we pre-specify these decisions for each
outcome considered. An additional analytic option in Stage II is to “break the match” and treat the
community as the unit of independence; we implement this as a sensitivity analysis for each outcome
considered.
Additional explanatory and descriptive analyses are also detailed below. We will provide descrip-
tive statistics of the baseline characteristics of study participants, stratified by region, and (among those
with baseline HIV status measured) baseline HIV status. Characteristics reported will include sex, age,
marital status (single, married, widowed, divorced/separated), education (no school, primary, secondary,
post-secondary), occupation, household wealth index (based on principal components analysis of baseline
household socioeconomic survey, as described in protocol), self-reported alcohol and contraceptive use, self-
reported prior HIV testing history, stable residence (≤6 months of past year outside of the community),
and mobility (≥1 month of past year outside of the community).
For each study outcome compared between arms, we will report formal consort diagrams as well as
participant flow diagrams enumerating inclusions and exclusions for all individuals contributing to the
analysis.
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The document is organized as follows. Section (2) provides an analytic plan for measurement and
estimation of three-year cumulative incidence of HIV for each community (Stage I). Section (3) provides
an analytic plan for estimation of and inference for the effect of the randomized intervention on this
outcome (Stage II). Section (4) provides corresponding power calculations under a range of scenarios. Sec-
tion (5) provides additional analyses of the HIV incidence outcome, including evaluation of the change in
annual HIV incidence over time. Section (6) provides analyses describing contextual factors potentially
contributing to observed HIV incidence patterns and investigating community-level drivers of HIV trans-
mission. Section (7) describes analyses of intervention uptake, including the HIV care cascade and plasma
HIV RNA suppression. Section (8) describes analyses of mortality, tuberculosis, and non-communicable
disease outcomes, as well as ART-associated toxicities and antiretroviral resistance. Full analysis plans
for (i) evaluating child and maternal HIV and health outcomes, (ii) supplemental analyses to investiage
HIV transmission patterns and drivers, and (iii) evaluating economic, educational, qualitative and costing
outcomes, are provided in separate documents.
1.1 Community selection and pair-matching
Fifty-four candidate communities meeting the following inclusion and exclusion criteria were initially se-
lected in Kenya and Uganda:
Inclusion criteria:
• Most recent census population between 9,000 and 11,000 individuals.
• Served by a government health center, already providing ART or a highly functioning health center
at one organizational level below those generally providing ART.
• Community leaders’ consent to ethnographic mapping.
• Accessibility to health center via a maintained transportation route.
• Community location with sufficient distance from other potential study communities to limit con-
tamination of intervention or control conditions (i.e. a buffer zone).
Exclusion criteria:
• Presence of ongoing community-based ART intervention strategies that provide treatment outside of
the current in-country treatment guidelines.
• An urban setting, defined as a city with a population of 100,000 or more inhabitants.
• National government not willing or opposed to support commodities needed for Community-based
Health Campaign (CHC), if provided by an outside organization.
Data on these communities were gathered with ethnographic mapping. Of the 54 communities, the
best 16 matched pairs (5 pairs in Western Uganda, 5 pairs in Eastern Uganda, and 6 pairs in Western
Kenya) were selected. Communities were matched based on region, population density, occupational mix,
trading centers, and migration.
1.2 Phase I study arms
One community in each matched pair was randomly assigned to “Control” and one to “Intervention”.
Control:
• Baseline household enumeration
• At baseline (Year 0) and Year 3, Community-based Health Campaigns (CHCs) with multi-disease
prevention and treatment services, including testing and referral for HIV, hypertension (HT), and
diabetes (DM)
• At baseline and Year 3, home-based or in-community testing for all CHC non-attendees
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• ART and HT/DM care according to national guidelines
Intervention:
• Baseline household enumeration
• Annual CHCs with multi-disease prevention and treatment services, including testing and referral
for HIV, HT, and DM
• Annual home-based or in-community testing for all CHC non-attendees
• Streamlined HIV Care:
– Immediate ART eligibility for all HIV+
– Supported linkage
– Rapid ART start
– Patient-centered care
– Enhanced retention
• Preplanned HIV cascade optimization
• HT/DM care delivered using streamlined model
The core intervention components and the cascade optimization strategy are detailed in a separate docu-
ment.
2 Stage I: Estimation of three-year cumulative HIV incidence in each
community
This section is focused on estimating the three-year cumulative HIV incidence in each community. We
first define the primary cohort for measurement. Then we formally define the Stage I target parameter
(community-specific three-year cumulative HIV incidence) and provide an overview of assumptions used to
identify this parameter. Finally, we describe our estimator of the community-specific cumulative incidence,
which incorporates incomplete CHC attendance, tracking coverage, and right-censoring due to death or
out-migration.
2.1 Defining the HIV Incidence Cohort
In each community, we seek to identify a cohort of baseline HIV-negative, adult residents on whom we will
measure the primary outcome of HIV seroconversion. This cohort is generated through
1. Enumeration of community residents during the baseline household census
2. Measuring HIV status and other variable at the baseline CHC
3. Tracking and evaluation, including home-based HIV testing, of residents who do not attend the
baseline CHC
We define enumerated residents as those who report (or are reported by a key informant) during the
census as living in a household within the community-specific geographic boundaries or those who link to
an enumerated household at the time of the baseline CHC. A resident is classified as stable if at the time
of census he or she reports (or is reported by a key informant) as living outside the parish/sublocation for
≤ 6 months of the preceding 12 months. A resident is classified as an adult if he or she is ≥ 15 years of
age at baseline.
We define the HIV Incidence Cohort as all enumerated, stable community residents who are ≥
15 years of age at baseline (adults), and who have documented HIV-negative serostatus by the close of
baseline tracking. We exclude individuals who have moved out of the community before the close of baseline
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tracking, as well as individuals who have a Ministry of Health clinic or laboratory record indicating HIV
care prior to their baseline HIV rapid antibody test.
2.2 Individual-level data
During the census, we measure individual-level data, including age, sex, occupation, location of residence
and marital status. For individuals attending a CHC or non-attendees who are successfully tracked, we
measure vital status, out-migration status, HIV status, individual-specific covariates including changes in
baseline enumeration variables and health outcomes as specified in the protocol. This population-based
testing (via the CHC with tracking) occurs annually in the intervention communities and at years 0 and 3
in the control communities.
To simplify notation and presentation, we define the following individual-level data for members of the
HIV Incidence Cohort:
• W : covariates measured during the baseline census and at the baseline CHC/tracking (e.g. age, sex,
marital status, occupation, education)
• C: an indicator of death or out-migration (defined below) by year 3
• ∆: an indicator of having HIV serostatus (and other covariates) observed at either the CHC or
through tracking at year 3
• I: an indicator of having a confirmed HIV-positive diagnosis at year 3 testing (CHC or post-CHC
tracking).
The observed data structure for individual i is thus
Oi = (Wi, Ci,∆i,∆iIi) . (1)
We also observe community-level covariates E (including the size of the incidence cohort in each community)
and the randomly assigned community treatment arm A. Because E and A are constant across a community
and thus will not impact estimation of the community-level outcome, we omit these variables from our
specification of the individual-level longitudinal data structure within a community.
2.2.1 Out-migration
When defining out-migration, we would ideally distinguish between migration patterns resulting in potential
exposures to HIV infection primarily within the SEARCH community (which more accurately reflect the
risk were an intervention rolled out more broadly) from migration patterns resulting in potential exposures
to HIV infection primarily outside the SEARCH community (which provide less relevant information about
the counterfactual exposure-level of interest). Such an ideal definition is unknown, likely to vary across
communities, and likely to depend on information difficult to measure in practice. Therefore, in the primary
analysis we use a definition of out-migration that attempts to avoid censoring individuals whose primary
exposure continues to occur within the community, and accept that as a result we may fail to censor people
whose primary exposure is outside the community.
An individual will be defined as out-migrated at year 3 if he or she (or a key informant if personal
report is not available) reports either of the following.
1. Spending > 6 months of the preceding year outside of the community.
2. Within the preceding 3 years, spending >12 contiguous months outside of the community.
Because less mobile individuals may also represent a selected subset of the population, we will conduct
a secondary analyses in which we do not censor at out-migration, as detailed below.
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2.3 Target parameter: Community-specific cumulative incidence
In each community-specific cohort, incident HIV cases are identified by repeat testing at year 3 (i.e. three
years after the baseline testing campaign), as described above and detailed in the protocol. HIV status
at year 3 will not be observed for all members of the Incidence Cohort due to death, out-migration, and
incomplete CHC attendance with incomplete success at tracking non-attendees. Let I(c, δ) denote the
counterfactual HIV infection status at year 3 under a hypothetical intervention to set censoring C = c and
measurement ∆ = δ. We define our Stage I target causal parameter as the probability that a member of
the HIV Incidence Cohort becomes infected with HIV during three years of follow-up under a hypothetical
intervention to prevent right-censoring and ensure knowledge of HIV status at year 3:
E[I(0, 1)] = P[I(0, 1) = 1]
In the primary analysis, death will be treated as a right-censoring event. In secondary analyses, we
will use HIV-free survival as a composite outcome. The decision not to treat death as a competing risk in
the primary analysis is based on the desire to define a community-level outcome that is not a function of
underlying mortality patterns. The decision not to use HIV-free survival for our primary analysis is based
on the expectation that the majority of mortality in our HIV Incidence Cohort will not be related to HIV
nor will it be strongly affected by the intervention.
In the primary analysis, out-migration will also be treated as a right-censoring event. We take this
approach because subjects who migrate out of an intervention community may be exposed to a higher risk
of HIV acquisition than exists within the community and thereby would dilute the effect of the intervention.
Further, this dilution would be less likely to occur if a comparable strategy were rolled out region-wide,
diminishing generalizability to the future context of interest. In secondary analyses we will (i) censor only
at death and (ii) evaluate the impact of the intervention on internally-derived HIV infections, as determined
through phylogenetic analysis and through self-reported suspected infection source among seroconversions.
We note that defining the community-specific outcome conditional on being a member of the HIV
Incidence Cohort avoids additional assumptions on factors determining baseline testing success and cor-
responding complexity during estimation. However, it introduces the possibility that the HIV Incidence
Cohort is not fully representative of the underlying community. Our design attempts to mitigate this risk
to the extent possible by using a prioritized tracking system at baseline. After completion of initial track-
ing, any age-sex strata in which < 80% of enumerated, stable, adult residents have known serostatus are
targeted for additional tracking. To investigate the representativeness of our baseline cohort, we will report
descriptive statistics comparing the age, sex and geospatial distribution of subjects seen at the baseline
CHC or tracked to those enumerated in the baseline census.
2.4 Identification and estimation
The community-specific cumulative incidence E[I(0, 1)] = P[I(0, 1) = 1] can be expressed as function of
the observed data distribution if the randomization assumption holds [5]:
I(0, 1) ⊥ C,∆ |W
This assumption allows censoring (by death or out-migration) and measurement (CHC attendance and
tracking success at year 3) to depend on the measured baseline covariates. It fails, however, if an individual’s
probability of either censoring or measurement depends on his or her interim HIV status. Reliance on this
identifying assumption would also imply the use of a full adjustment set (i.e. all baseline covariates) during
estimation of the Stage I target parameter. This would result in more complex estimators with unclear
benefit to overall estimator performance (bias, mean squared error, confidence interval coverage, and Type
I error control) when evaluating the impact of the intervention (Stage II target parameter). (For example,
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use of a full adjustment set might reduce performance if bias occurs in the same direction in intervention
and control arms and/or if certain covariates strongly predict censoring and measurement but have a
minimal impact on the outcome.)
In the primary analysis, we therefore rely on the following stronger identifiability assumption:
I(0, 1) ⊥ C,∆.
While HIV infection between baseline and year 3 could plausibly affect subsequent censoring or measure-
ment (resulting in a violation of these assumptions), we minimize the extent to which this bias is likely
to be differential in treatment and control arms by relying on the equivalent measurement structures in
both arms. (In other words, we only use data from baseline and year 3 for estimation of the three-year
cumulative incidence in both study arms.) Further, under a range of plausible scenarios, the direction of
the bias in estimates of community-specific cumulative incidence is likely to be the same in control and
intervention arms, and thus result in some degree of bias cancellation for estimates of the intervention
effect. Simulations, under a range of both plausible and extreme informative measurement and censoring
processes, verify this prediction and show good confidence interval coverage and type I error control for
effect estimates based on this approach.
In the primary analysis, our target statistical estimand is then
E
[
I
∣∣C = 0,∆ = 1] = P [I = 1∣∣C = 0,∆ = 1] . (2)
Community-specific HIV cumulative incidence will be estimated as the corresponding simple empirical
proportion of Incidence Cohort members who remain alive and resident in the community at year 3 with
HIV status measured at year 3 testing who are confirmed to be HIV-positive at year 3 testing.
In sensitivity analyses, we will use baseline covariates W to adjust for potentially informative censoring
and missingness. When implementing these secondary analyses with a full adjustment set, we will use
targeted maximum likelihood estimation (TMLE) to estimate
EWE
[
I
∣∣C = 0,∆ = 1,W )] , (3)
with Super Learning for estimation of the outcome regression E
[
I
∣∣C = 0,∆ = 1,W ] and propensity score
P[C = 0,∆ = 1|W ] [6–8]. We will also conduct additional sensitivity analyses in which we use an analogous
approach to further adjust for known interim HIV diagnosis (acknowledging that our measurement of
interim diagnosis is expected to be greater in the intervention arm). Finally, while by design we expect
very similar follow-up times in intervention and control communities, in further sensitivity analyses we
will estimate community-specific HIV incidence rates over the three year follow-up period (using analogous
data structures in intervention versus control arms and assuming incident infections occur at the midpoint
between the baseline negative HIV test and confirmed seroconversion at year 3).
Additional secondary analyses will use the annual data available in the intervention communities to
investigate HIV incidence over time and factors contributing to ongoing transmission (as detailed further
below and in the supplementary analysis plan focused on drivers of transmission). In addition, we will report
estimates of the three-year cumulative HIV incidence for each community, and compare characteristics of
cohort members with HIV status known versus missing at follow-up year 3.
3 Stage II: Estimation of the intervention effect on HIV incidence
This section is focused on obtaining a point estimate and inference for the relative difference in 3 year HIV
cumulative incidence between intervention and control arms. We first describe the community-level data
and implications of the pair-matched design. Then we specify the target parameter for Stage II as the
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expected HIV incidence under the intervention relative to the expected HIV incidence under the control
for the study communities. Primary analysis weights each community equally; sensitivity analyses will
weight individuals equally.
Next we discuss two estimation strategies - unadjusted and adjusted. Our primary analysis will be
adjusted.
3.1 Community-level data and adaptive pair-matching
Given estimates of the community-specific cumulative HIV incidence generated in Stage I, the observed data
can be simplified to the cluster-level. Let E represent the baseline community-level covariates, including
measures from the ethnographic mapping (e.g. region, proximity to trucking routes, occupational mix),
the census (e.g. age distribution, sex ratio, community size), and the baseline CHC with tracking (e.g.
HIV prevalence). The exposure variable A equals 1 if the community was randomized to the intervention
arm and equals 0 if the community was randomized to the control arm. The outcome Y is the estimated
community-specific three-year cumulative incidence of HIV (obtained from Stage I). Thereby, the observed
data for SEARCH community j can be denoted
Oj = (Ej , Aj , Yj)
for j = {1, . . . , 32}. We use J to denote the total number of communities in the study (J = 32).
As described in Section 1.1, fifty-four communities were identified from rural Uganda and Kenya as
potential study sites. From these candidate communities, the J/2 = 16 pairs (5 in Western Uganda, 5 in
Eastern Uganda, and 6 in Kenya) that were best matched on baseline covariates were selected. We consider
this pair-matching scheme to be adaptive, because the partitioning of the study communities into matched
pairs was a function of the baseline covariates of all candidates. This adaptive design has important
implications for estimation and inference [1, 2, 9]. Given the covariates of all candidate communities, the
observed data can be represented as J/2 conditionally independent random variables:
O¯k =
(
Ok1, Ok2
)
=
(
(Ek1, Ak1, Yk1), (Ek2, Ak2, Yk2)
)
where the index k = {1, . . . , 16} denotes the partitioning of the candidates into matched pairs according
to similarity on their baseline covariates. Throughout, subscripts k1 and k2 denote the first and second
communities within matched pair k. The treatment mechanism is known; with probability 0.5, the first unit
is randomized to the intervention and the second to the control. Throughout we assume that the baseline
covariates and the intervention assignment in one community do not affect the outcome of another study
community. In other words, we assume the study communities are causally independent. Self-reported
residence location of suspected infection source among seroconversions, as well as linkage of nominated
social network contacts across communities, will be used to evaluate the extent of possible spill-over across
communities.
3.2 Target parameter: Incidence ratio
Our goal in the primary analysis is to estimate the effect of the SEARCH intervention on three-year
cumulative HIV incidence for our study communities. Let Yj(a) denote the counterfactual cumulative HIV
incidence under intervention level A = a for community j, and let
ψ(a) =
1
J
J∑
j=1
Yj(a)
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be the empirical mean for the study communities. Then our target of inference is the sample cumulative
incidence ratio
ψ(1)
ψ(0)
=
1
J
∑J
j=1 Yj(1)
1
J
∑J
j=1 Yj(0)
This parameter is the average incidence under the intervention for the 32 study communities divided by the
average incidence under the control for the 32 study communities. As discussed in the following sections,
estimation and inference for the sample parameter ( 1J
∑J
j=1 Yj(a)) are identical to estimation and inference
for the conditional parameter (1/J
∑
j E [Yj(a) | Ej ]) and analogous to the population parameter E[Y (a)].
The distinction lies in interpretation and inference, with estimators of the sample parameter often being
less variable (more precise) than those of the population parameter [2, 10–12].
3.3 Estimation of the intervention effect
An intuitive estimator is the average outcome among intervention units divided by the average outcome
among the control units:
Unadj. =
ψˆ(1)
ψˆ(0)
=
Eˆ(Y |A = 1)
Eˆ(Y |A = 0) .
When the measured covariates are predictive of the outcome, this simple estimator is often inefficient as it
fails to adjust for measured covariates (e.g [13–18]). Irrespective of how well matching is performed, there
is likely to be some residual imbalance on pre-intervention determinants of the outcome within matched
pairs. Furthermore, there are additional baseline covariates, such as baseline HIV prevalence, that are
predictive of the outcome but were unavailable during the matching process. In general, adjusting for
baseline covariates during the analysis can reduce variance without bias, even in small trials (e.g. [17, 18]).
Therefore, for the primary analysis we will use targeted minimum loss-based estimation (TMLE) to
provide an unbiased and more efficient estimate of the intervention effect [2, 6]. For comparison, in
secondary analyses we will also implement the unadjusted estimator. The TMLE for the sample incidence
ratio is given by the following substitution estimator:
TMLE =
ψˆ∗(1)
ψˆ∗(0)
=
1
J
∑J
j=1 Eˆ∗(Yj |Aj = 1, Ej)
1
J
∑J
j=1 Eˆ∗(Yj |Aj = 0, Ej)
where Eˆ∗(Y |A,E) denotes a targeted estimate of the conditional mean function E(Y |A,E). In general,
this targeting step is used to achieve the optimal bias-variance trade-off for the parameter of interest and
to solve the efficient score equation [6, 19]. Informally, this targeting step incorporates information in the
known or estimated exposure mechanism P(A|E). The algorithm is detailed in [6].
Our a priori -specified library of candidate estimators of the expected outcome given intervention arm
and covariates, E(Y |A,E), consists of community-level logistic regressions, each with an intercept, a main
term for the exposure, and either one additional covariate (baseline HIV prevalence or baseline male
circumcision coverage), or no additional variable (unadjusted estimator). Our a priori -specified library
of candidate estimators of the known exposure mechanism P(A|E) = 0.5 is defined by logistic regression
models with an intercept and a main term for one remaining covariate. For example, if baseline prevalence
is selected as the adjustment variable in E(Y |A,E), the corresponding logistic regression is removed from
the set of candidate adjustment variables for the exposure mechanism P(A|E). To further reduce the
library size, we restrict the candidates such that if the unadjusted estimator is selected for estimation of
E(Y |A,E), we will also not adjust when estimating the known exposure mechanism. We will use leave-one-
pair-out cross-validation to select the candidate TMLE, with candidate selected to minimize the estimated
variance (described in the following section). The procedure is detailed in [4].
11
In anticipation that certain communities may be poorly matched on baseline drivers of incidence, a
challenge only partially addressed by covariate adjustment, we will also conduct two pre-specified secondary
analyses: excluding the matched pair with the highest discrepancy on baseline prevalence and excluding
the matched pair with the highest discrepancy on baseline male circumcision coverage. Standard power
calculations suggest that the reduction in matched pair coefficient of variation km offsets the loss in the
number of independent units and thus degrees of freedom (Figure 2) [3]. Finally, as a sensitivity analysis,
we will “break the match”, treating the community as the independent unit and including region in the
pre-specified candidate adjustment variables.
3.4 Inference
As established in [2], both the unadjusted estimator and TMLE are asymptotically linear and normally
distributed estimators of treatment-specific mean: ψ(a) = 1J
∑J
j=1 Yj(a). Thus, the limit distribution of
the standardized estimator is normal with mean 0 and variance given by the variance of its influence curve.
Under pair-matching, an asymptotically conservative approximation of the influence curve for the TMLE
is given by
ˆIC(a; O¯k) =
1
2
[
ˆIC(a;Ok1) + ˆIC(a;Ok2)
]
with ˆIC(a;Oj) =
I(Aj = a)
Pˆ(Aj = a|Ej)
(
Yj − Eˆ∗(Yj |Aj = a,Ej)
)
For the sample incidence ratio ψ(1)/ψ(0), we apply the Delta method to test the null hypothesis and create
95% confidence intervals on the log-scale:
log[ψ(1)/ψ(0)] = log[ψ(1)]− log[ψ(0)]
The influence curve for the log(TMLE) =log[ψˆ∗(1)/ψˆ∗(0)] for matched pair k is given by
ˆICtmle(O¯k) =
1
ψˆ∗(1)
ˆIC(1; O¯k)− 1
ψˆ∗(0)
ˆIC(0; O¯k)
The unadjusted estimator is a specific case of TMLE, where we replace the targeted Eˆ∗(Y |a,E) with the
empirical Eˆ(Y |a) and the estimated exposure mechanism Pˆ(a|E) with empirical Pˆ(a) = 0.5.
Inference for the intervention effect will be based on the estimated influence curve and the Student’s
t-distribution with 15 degrees of freedom. Specifically, on the log-scale we will estimate the variance by
taking the sample variance of the estimated influence curve divided by J/2, construct Wald-Type confidence
intervals, and test the null hypothesis of no average effect. Confidence intervals and two-sided hypothesis
testing will be conducted at a 5% significance level. Finally, the (log) point estimate and confidence intervals
will be exponentiated to be on the original scale. While a single hypothesis test will be conducted on the
relative scale, effect measures and corresponding confidence intervals will also be reported for the absolute
scale (ψ(1) − ψ(0)) to facilitate alternative uses. Finite sample simulations suggest that under plausible
scenarios the adjusted estimator provides modest to substantial efficiency gains and corresponding power
improvements, while retaining good type I error control and 95% confidence interval coverage.
4 Power Calculations and Simulation Results for Primary Outcome
We first present standard power calculations for cluster randomized trials under a range of plausible and
conservative assumptions. Then in Section 4.2, we present full simulations evaluating the performance of
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our proposed two-stage estimator. We report the attained power under a range of scenarios for changes
in the guidelines for ART initiation in the control arm and achieved ART coverage. We also demonstrate
good confidence interval coverage and type I error control.
4.1 Classical power calculations
Our initial power calculations were based on the standard sample size formulas for an unadjusted compar-
ison of proportions in a pair-matched cluster randomized trial with two arms [3]. Using a two-sided test at
a 5% level of significance, these calculations indicated that 16 matched pairs would provide at least 80%
power to detect a 40% reduction in the three-year HIV cumulative incidence under a conservative value
for the matched pair coefficient of variation (km) and to detect smaller effect sizes under more plausible
km values. Figure 1 shows a graph of the percent reduction detectable with 80% power under a range of
deviations from the following assumptions.
• We assumed a stable adult resident size of 5,000, a baseline HIV prevalence of 10%, measurement of
HIV status at baseline among 80% of residents, and measurement of HIV status at the final year on
75% of those HIV-negative at baseline. This yields approximately 2700 residents in each community
who are in the HIV Incidence Cohort and have their serostatus known at year 3. While the exact
cohort size will vary, if the actual sample size per community is at least 2700 individuals, then these
calculations can be considered conservative. We further note that moderate deviations from this
number of individuals are not expected to have strong impacts on power.
• We assumed that the three-year cumulative HIV incidence was 1% in control communities. This
estimate was considered conservative given the available literature, which suggested that HIV trans-
mission rates are approximately 0.5% to 2% [20–22]. For example, assuming a current incidence
density of 0.5 cases per 100 person-years and allowing for a 10% decline in transmission rate per year
in the absence of the intervention (due to concurrent prevention activities and expansion of ART)
would suggest a three-year cumulative incidence of approximately 1.34%. If the three-year cumulative
incidence is 1.34% in control communities, then these calculations can be considered conservative.
• We assumed a matched pair coefficient of variation km of no greater than 0.4. While ideally external
data would be available to the inform its selection, the generalizability of km values across studies is
limited. Specifically, km depends (among other things) on which covariates are used for matching,
how close a match is achieved, and the strength of association between these covariates and the
outcome. Furthermore, recent work has demonstrated the instability of estimates of km based on
empirical data [23]. Prior studies, performed in similar settings, have assumed a km closer to 0.25
(e.g. Project ACCEPT [personal communication] and the Mwanza Trial [24]). With the above
assumptions, these calculations indicated that would be powered to detect a 40% reduction with
km = 0.4, a 33% reduction with km = 0.3, and a 27% reduction with km = 0.2.
We also expect that these calculations are conservative because of the precision gained through covariate
adjustment during the analysis. Adjustment with TMLE should improve power by reducing the variability
of the estimator and resulting in a less conservative variance estimator [2]. On the other hand, these
calculations may be anti-conservative if there is substantial heterogeneity in HIV incidence within study
regions and we match poorly on those sources of variability within region.
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Figure 1: Effect size (in percent reduction) that we are powered to detect at 80%, while varying the control cumulative incidence
(CI), the matched pair coefficient of variation km, and the number of individuals in the HIV Incidence Cohort, who have their
status known at year 3. The calculations were based on the standard sample size formulas for an unadjusted comparison of
proportions in a pair-matched cluster randomized trial with 32 communities total [3].
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Figure 2: Effect size (in percent reduction) that we are powered to detect at 80% using all 16 matched pairs or dropping 1
poorly-matched pair resulting in a 0.05 reduction in the matched pair coefficient of variation km. The calculations were based
on the standard sample size formulas for an unadjusted comparison of proportions in a pair-matched cluster randomized trial
with two arms [3].
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4.2 Simulations and mathematical modeling
We used simulations to examine the performance of our proposed two-stage effect estimator. We first used
a mathematical model to generate plausible country-specific incidence curves under a range of assumptions
regarding scale-up of ART. These incidence curves were the basis for full hierarchical simulations that
incorporated a number of the challenges faced by our primary outcome analysis, including: (i) differential
HIV testing processes in the intervention and control arms, (ii) possibly differential informative right-
censoring (due to death and out-migration) by intervention arm and individual HIV status, (iii) possibly
differential informative measurement (through CHC attendance and tracking success) by intervention arm
and individual HIV status, (iv) the inability to match on all measured baseline covariates predictive of the
outcome, (v) few conditionally independent units, and (vi) rare outcomes.
4.2.1 Simulation setup
The following describes the data generating experiment for each of the 32 communities in the simulated
study. To reflect the underlying processes, including differential HIV testing between study arms, we
simulated the complete data at t = {0, 1, 2, 3} for all individuals in each community. As previously
discussed, our estimators only use data measured at t = {0, 3} in both arms. We first describe the
generation of the community-level data and then the individual-level data. Throughout, we use i to denote
individuals in community j at time t.
For community j, nine baseline community-level covariates were generated by drawing from a multi-
variate normal. The correlation between the first three covariates {E1j , E2j , E3j} and between the second
three covariates {E4j , E5j , E6j} was approximately 0.25, while the correlation between the last three
{E7j , E8j , E9j} was 0. Region Rj was set to reflect the study design with 10 communities from Eastern
Uganda, 10 communities from South Western Uganda, and 12 communities from Kenya. Pre-intervention
HIV prevalence Zj was generated to reflect baseline study data and as a function of region Rj , covariates
{E1j , E4j , E7j}, and random noise UZj . Baseline coverage of male circumcision Z2j was also generated to
reflect baseline study data.
The community-specific hazard of HIV infection under study arm a at time t, denoted hjt(a), was
generated as a function of the projected incidence rate1, community covariates {E2j , E5j , E8j}, prevalence
Zj , circumcision coverage Z2j , and random noise that was correlated within a community over time. The
number of stable, adult residents was drawn from a uniform with minimum 4,000 and maximum 6,000
for Ugandan communities and with minimum 3,500 and maximum 5,480 for Kenyan communities. The
baseline coverage of HIV testing (via the baseline CHC and tracking) was drawn from a uniform with
minimum of 80% and maximum of 90%.
For individual i in community j at time t = 0, baseline HIV status Yij0 was generated as a function the
baseline community-level prevalence Zj and random noise that was correlated within an individual over time
UYijt . Baseline measurement (CHC attendance or post-CHC tracking) ∆ij0 was generated as a function
of the community-specific coverage probability at baseline and random noise that was correlated within
an individual over time U∆ijt . The resulting HIV Incidence Cohort was then defined as all community
members who were HIV-negative and observed at baseline: Yij0 = 0 & ∆ij0 = 1. (All community members
were assumed to be living, stable residents at baseline: Cij0 = 0 for all i and j.)
For the remaining years of the trial t > 0, HIV status Yijt was generated as a function the community-
specific hazard hjt(a), individual-level covariates of age, sex, and circumcision (among males), and random
noise UYijt . (The individual-level covariates were also generated to reflect baseline data.) Censoring,
representing both death and out-migration, was generated as a function of the study arm A, underlying
1The incidence rate of HIV under exposure-level A = a at time t was informed by Goals module from the Spectrum System
of Futures Institute, as detailed in Section 4.2.3.
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HIV status Yijt, and random noise that was correlated within an individual over time UCijt . For simplicity,
we assumed that past measurement did not affect censoring at t. We explored a variety of censoring
mechanisms, ranging from non-differential to quite differential by study arm and underlying HIV status.
We also explored a “mixture” scenario, where each community was randomly and independently assigned a
censoring scenario with equal probability. The mixture scenario reflects that censoring might be operating
in different ways in different communities.
We also explored two measurement (CHC attendance and tracking) mechanisms. In the first, the
observation status after baseline ∆ijt (for t > 0) was generated as function of the study arm A, underlying
HIV status Yijt, censoring Cijt, and random noise U∆ijt . In the second, the observation status ∆ijt was
generated as a function of the study arm A, known HIV+ status, censoring Cijt, and random noise U∆ijt .
Here, HIV+ status was “known” if an individual tested positive at a prior CHC or subsequent tracking. For
each type of measurement mechanism (i.e. dependent on underlying HIV status or “known” HIV status),
we explored a variety of scenarios, ranging from non-informative to quite informative by HIV status and
treatment arm. As before, we generated a “mixture” scenario, where each community was randomly and
independently assigned a measurement scenario with equal probability. By definition, the observation
probability was 0 for control community members at t = {1, 2}.
Given simulated data under both study arms, we calculated as the true value of our target parameter,
the sample incidence ratio:
ψ(1)
ψ(0)
=
1
J
∑J
j=1 Yj(1)
1
J
∑J
j=1 Yj(0)
where Yj(a) denotes the three-year cumulative HIV incidence for community j under the exposure-level
(A = a) and under a hypothetical intervention to prevent censoring and ensure final knowledge of HIV
status among all members of the community-specific HIV Incidence Cohort.
4.2.2 Adaptive pair-matching, intervention randomization, and estimation
Using the non-bipartite matching algorithm npbMatch [25], we pair-matched communities within region R
on predictors of baseline prevalence {E4, E7}. The intervention A was randomized within the matched
pairs. For Stage I estimation of the community-specific cumulative incidence of HIV, we implemented
the unadjusted estimator based on a simple empirical mean. For Stage II estimation of the intervention
effect, we implemented both the unadjusted estimator as well as the pre-specified data-adaptive procedure,
described in Section 3.3. Inference was based on the estimated influence curve. For confidence interval
construction and two-sided hypothesis testing, we used Student’s t-distribution with 15 degrees of freedom
and a 5% significance level. These estimation procedures were previously detailed in Sections 2 and 3.
4.2.3 Mathematical modeling
The Goals module from the Spectrum System of Futures Institute was used to provide country-specific
projections of the prevalence and incidence of HIV under the SEARCH intervention and under the control
(http://www.futuresinstitute.org/spectrum.aspx). The software was originally developed by the
Futures Group, in collaboration with Family Health International, and is supported by UNAIDS and the
Gates Foundation, among others [26–28].
The mathematical model was parameterized with published data from national and regional surveys in
Uganda and Kenya on HIV prevalence and coverage of male circumcision (Nyanza region of Kenya) [21, 29–
33]. At baseline, we assumed 75% of eligible populations in Uganda and 66% in Kenya were on ART and
virally suppressed. The model was also parameterized to reflect post-baseline changes in ART eligibility
as well as scale-up of ART coverage. Specifically, the inputs for the control arm reflected in-country
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implementation of the guidelines to change CD4-based eligibility from ≤ 350 cells/µL to ≤ 500 cells/µL
starting in 2014; universal eligibility for key populations, including pregnant women, tuberculosis/HIV co-
infected and discordant couples, starting in 2015; and universal eligibility for all HIV+ starting in 2016. We
generated incidence curves in the control arm under these guidelines and a range ART coverage trajectories
(control scenarios A-B), in which 62-67% of eligible populations under expanded guidelines were on ART
and virally suppressed by year 3 of the study. These were then contrasted with the projected incidence
curves under the SEARCH intervention, assuming 73% of all HIV+ were on ART and suppressed by 18
months after baseline (Figure 3).
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Figure 3: Projected incidence of HIV for Uganda and for Kenya in percent (%) as informed by the Goals module in the Spectrum
System of Futures Institute [26–28]. The projected incidence rates (in percent) under the control scenario A (less conservative),
control scenario B (more conservative) and the intervention arm are given by blue, green and red lines, respectively.
4.2.4 Results
The true value of the sample effects depends on the n = 32 communities in the study. Over the 500
simulated data sets, Table 1 shows the average value of the sample incidence ratio: ψ(1)/ψ(0). The
variance of the effect and the average matched pair of coefficient of variation km are also given. The
scenarios explored are described in Figure 3.
ψ(1)/ψ(0) V ar[ψ(1)/ψ(0)] km
Scenario A 0.695 7.04E-5 0.372
Scenario B 0.704 7.55E-5 0.366
Table 1: The average values and variance of the causal parameter across 500 repetitions of the data generating experiment.
ψ(1) refers to the average risk (three-year cumulative incidence of HIV) under the intervention, and ψ(0) refers to the average
risk under the control. Recall this parameter changes with each sample, and V ar[ψ(1)/ψ(0)] gives the variability of the effect
across the 500 runs. Finally km is the average value of the estimated matched pair coefficient of variation.
Table 2 illustrates the performance of the estimators over 500 simulated data sets. Specifically, we
compare the unadjusted estimator and the TMLE. Both estimators were unbiased. As expected, there was
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an efficiency gain with adjustment through TMLE. The attained power ranged from 81 to 83% with the
unadjusted and from 88 to 91% with the TMLE. Throughout, there was nominal to conservative confidence
interval coverage and type I error control (Table 2). Simulation results under alternative matching schemes,
differential censoring, and informative missingness are available elsewhere.
Unadjusted Estimator TMLE
bias std. err. tstat cover power bias std. err. tstat cover power
Scenario A 1.46E-3 1.34E-2 -3.31 0.98 0.83 2.45E-4 9.85E-3 -3.91 0.95 0.91
Scenario B 2.10E-3 1.34E-2 -3.18 0.97 0.81 1.28E-3 1.01E-2 -3.73 0.95 0.88
bias std. err. tstat cover α bias std. err. tstat cover α
Null 5.60E-3 1.31E-2 -0.00 0.97 0.03 5.06E-3 9.30E-3 -0.00 0.95 0.05
Table 2: The bias (average deviation between the point estimate and sample-specific true value), average standard error
(estimated with the influence curve), average value of the test statistic (point estimate divided by standard error estimate),
confidence interval coverage (proportion of intervals containing the true parameter value), attained power (proportion of studies
correctly rejecting the false null hypothesis), and type I error rate α (proportion of studies falsely rejecting the true null
hypothesis) of the unadjusted estimator and the TMLE over 500 simulated trials. The null scenario was simulated by generating
incidence as if the intervention had 0 impact (i.e. the hazard of HIV infection under the intervention equaled that of the control).
5 Additional analyses of incident HIV infection
5.1 Subgroup analyses for the primary outcome
For the following baseline subgroups, we will report estimates of the three-year cumulative HIV incidence
by treatment arm (conducted as for Stage I of the primary analysis) and estimate the effect of the random-
ized intervention on this outcome, including a formal hypothesis test of no intervention effect (conducted
as for Stage II of the primary analysis): sex, age (15-24 years and > 24 years), marital status (ever vs.
never married), non-mobile populations (< 1month of past year spent away from the community), and
uncircumcised men. We will further compare intervention versus control incidence for each region sepa-
rately; Stage II analyses for region-specific comparisons will be unadjusted due to the small number of
communities.
In addition, for the following baseline strata, we will report estimates of the three-year cumulative
HIV incidence by treatment arm: adolescents (15-24 years; overall and by sex), adults aged 15-49 years,
adults aged 15-59 years, mobile populations (≥1month of past year away from the community), non-stable
residents (>6month of past year away from the community), circumcised men, students, and fishermen.
5.2 Change in HIV incidence over time
To understand the changes in HIV incidence over time, we will estimate the annual incidence of HIV in
the intervention arm, making use of community-based testing results from annual CHC and tracking to
construct three annual incidence cohorts. Specifically, for testing years t ∈ {0, 1, 2} (where t = 0 denotes
study baseline), among an open cohort of adult (aged ≥ 15 years at year t) residents (including inmigrants
identified through the follow-up year 3 re-census) who test HIV-negative at year t, we will estimate HIV
incidence during the subsequent year of study follow-up (infection by testing round t+ 1). Estimates will
be reported overall, and further stratified by region, gender, age (≤ 24, > 24), and circumcision status, as
well as reported for each community.
Primary analyses will report estimates of annual HIV incidence rate among individuals with measured
HIV status at year t+1, assuming incident infections occur at the mid-point between negative and positive
tests, excluding individuals who have out-migrated during the year. Sensitivity analyses will (i) not censor
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at outmigration; (ii) restrict to baseline stable residents (acknowledging the potential depletion of high
risk individuals, even after adjustment for measured differences); (iii) calculate annual risks vs. rates using
a 95-day annual testing window; and (iv) adjust for potentially informative incomplete ascertainment of
HIV status (including due to censoring by death or outmigration in the interim year).
The primary analysis to evaluate the change in annual HIV incidence rate over time will use Poisson
regression with generalized estimating equations, and with standard errors estimated using an robust
sandwich estimator based on an an exchangeable working covariance matrix. We will estimate change over
time both with and without adjustment for changes in the characteristics of the measured incidence cohort.
We will further estimate the change in annual risk of HIV acquisition using a pooled individual interval-
level TMLE, with the exposure of interest defined as the time interval, and influence curve-based estimation
of the standard error, respecting the community as the independent unit (i.e. allowing for dependence of
observations within a community conditional on the covariates included in the adjustment set), and using
the t-distribution as the basis for statistical inference.
5.3 Individual-level predictors of HIV seroconversion
We will provide descriptive statistics of members of the HIV Incidence Cohort who seroconverted by year 3,
including the distributions of age, sex, and other baseline characteristics, stratified by arm and by region.
For each of the following baseline predictor variables, we will report unadjusted associations and adjusted
variable importance measures on the relative scale (statistical analogs of the causal risk ratio), treating
each baseline predictor in turn as the intervention variable, and the remainder (together with region) as
the adjustment set. Baseline predictors to be considered will include sex, age, marital status, education,
occupation, household wealth index, mobility, circumcision (among men), self-reported alcohol use, self-
reported contraceptive use, relationship to head of household, polygamy, self-reported prior HIV testing,
and baseline testing location (CHC vs. tracking).
Variable importance measures will be estimated with pooled individual-level TMLE with the community
treated as the independent unit for influence curve-based variance estimation and with inference based on
the Student’s t-distribution. Secondary analyses will treat individuals as the independent unit and include
community as a fixed effect. Variable importance measures will be calculated with and without adjustment
for potentially informative censoring and measured HIV status, and will be reported overall and stratified
by arm, region and sex.
5.4 Potential sources of HIV seroconversions and internally-derived HIV infections
5.4.1 Discordant spouses
We will provide descriptive statistics of known discordant couples at baseline. For the overall pooled HIV
Incidence Cohort (pooled over all communities and arms) and each arm-specific HIV Incidence Cohort
(pooled over all communities within each arm), we will report the number and proportion of seroconversions
that occurred among baseline discordant couples.
5.4.2 Seroconversion interviews
Based on qualitative interviews of participants who seroconverted, we will create descriptive tables of the
self-reported suspected source of HIV infection. Using self-reported residence of suspected infection source,
we will classify seroconversions as internal or external to the seroconverter’s community of residence (or
“unable to classify”). We will estimate an alternative community-level HIV incidence outcome, defined
as the probability of becoming infected over the 3 years of the study by a suspected source resident in
the same community (“internally derived” by self-report). We will conduct analyses analogous to those
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performed for the primary outcome to compare the probability of becoming infected by an internally
derived virus (with and without including seroconversions with unknown source) across treatment arms
and among subgroups.
5.4.3 Phylogenetic analyses
Viral consensus sequences will be used to estimate phylogenetic relationships and genetic distances between
HIV viruses sampled during the study. These data, together with additional reference sequences, will be
used to classify incident HIV infections among community cohort members as linked or not linked to
previously documented infections among community members [34].
An internally-derived infection will be defined as a seroconversion classified, based on sequence analysis,
as linked to a previously measured virus from a member of the same community. An externally-derived
infection will be defined as a seroconversion classified as unlinked to a previously measured virus from a
member of the same community. We will estimate an alternative community-level HIV incidence outcome,
defined as the probability of an HIV Incidence Cohort member becoming infected over the 3 years of
the study by an internally-derived virus. We will conduct analyses analogous to those performed for the
primary outcome to compare the probability of becoming infected by an internally derived virus across
treatment arms and among subgroups. We will also provide descriptive statistics and evaluate predictors
of internally-derived infection.
In addition, characteristics of transmission clusters detected using phylogenetic data will be reported,
including age, sex, occupation, mobility, discordant spouses, shared household membership, and geospatial
proximity. Information from seroconversion interviews will further be used to identify possible transmission
links and shared risks between cluster members.
6 Community-level descriptive and explanatory analyses
At baseline and year 3, stratified by intervention arm, we will estimate the following potentially important
drivers of HIV incidence: HIV prevalence, male circumcision coverage (traditional, medical, and overall),
HIV RNA suppression, and migration status. Sexual behavior and mixing patterns will be further in-
vestigated in a complimentary nested study that will provide more detailed measurement and analysis of
mobility.
6.1 Community-level drivers of HIV incidence
6.1.1 HIV prevalence
We will report HIV prevalence at baseline and year 3 among all adult residents. We will estimate prevalence
by community, region, treatment arm, age-sex strata (here and throughout this section, using as age cate-
gories 15-24, 25-34, 35-44, 45-54, and >55 years), and baseline mobility (here and throughout this section,
using as primary mobility categories those reporting <1mo away vs. ≥1mo away from the community in
past year). We will compute both unadjusted prevalence estimates based on the empirical proportion of
HIV-positive individuals among those tested, and adjusted estimates, accounting for incomplete coverage
of HIV testing. For the latter, we will use TMLE to adjust for ways in which individuals tested for HIV
are different from those not tested [35, 36]. Among individuals who test HIV-positive at baseline, we will
report the proportion in the following CD4 strata: <50 cells/µl, 50-200 cells/µl, 201-349 cells/µl, 350-500
cells/µl, and >500 cells/µl.
20
6.1.2 Male circumcision coverage
At baseline and year 3, we will report the proportion of adult male residents who are circumcised (overall
and by medical vs. traditional means). We will also report coverage by community, region, treatment
arm, age strata, and baseline mobility. Estimates will be based on the unadjusted empirical proportion
of circumcised adult males among those seen at the CHC/tracking and adjusted estimates, accounting for
incomplete measurement with TMLE to adjust for ways in which individuals seen are different from those
not [35, 36].
6.1.3 Plasma HIV RNA ≥500 copies/ml
Among individuals known to be HIV-positive at baseline, we will report the proportion in the following
baseline plasma HIV RNA strata: <500 cps/ml, 500-999 cps/ml, 1,000-9,999 cps/ml, 10,000-99,999 cps/ml,
≥100,000 cps/ml).
We will estimate the proportion of the total adult population, and of the HIV-positive adult population,
with plasma HIV RNA ≥500 copies/ml at baseline and at year 3, adjusting for incomplete measures of HIV
status and HIV RNA levels among HIV-positive individuals, as detailed in Section 7 (“Population-level
HIV RNA metrics”); sensitivity analyses will consider a threshold of 1000 copies/ml. Estimates will be
reported by community, region, treatment arm, age-sex strata, and baseline mobility. We will further use
adjusted variable importance measures, estimated using a pooled individual-level TMLE with community
included as a fixed effect, to evaluate predictors of having plasma HIV RNA level ≥500 copies/ml at year
3.
In addition, to investigate relationships between community-level HIV viral replication and HIV inci-
dence, we will estimate the proportion of cumulative person time (of adult person time in the community
contributed by all residents, not only those who are HIV-positive) with unsuppressed HIV viral replication
(plasma HIV RNA >500 copies/ml) within each community. Estimation of such a metric is complicated
by different measurement structures in the intervention and the control arms. Specifically, HIV status,
plasma HIV RNA levels, and in-migration to the study communities are measured at only two time points
in the control communities. In contrast, in the intervention communities, HIV status is measured annually
at CHC/tracking; HIV RNA is measured both at annual CHC/tracking and during interim clinic visits,
and in-migrants to the community are (partially) ascertained annually. Further, a linear extrapolation
between community-specific proportions unsuppressed at baseline and year 3 will fail to detect any change
in the shape of the suppression curve over time, as might be expected to result from the intervention (for
example, due to expanded ART eligibility at baseline and facilitated linkage with streamlined ART delivery
post-baseline in the intervention communities).
We will therefore estimate the total unsuppressed person-time for each community with an algorithm
that relies on baseline and year 3 measures of HIV status, HIV RNA level, and migration status only (to
ensure comparability between arms), but also incorporates interim data on ART initiation date (ascertained
in both arms).
For these analyses, adult person-time in a community will begin at the first of the start of the
community-specific baseline CHC (for baseline residents aged ≥ 15 years at baseline) or first date at
which an individual is a resident (including in-migration) and is aged 15 years old or more. Adult person-
time in the community will end at the first of (i) date of death, (ii) date of out-migration (if any), and (iii)
end of year 3 tracking. Within this person-time, we will estimate the total person-time with unsuppressed
HIV RNA levels in the population using the following algorithm.
1. Estimate total unsuppressed time between baseline and year 3 contributed by adult residents diag-
nosed with HIV at or before study baseline.
21
• Assume baseline HIV-positive residents who are suppressed at baseline and suppressed at year
3 are never unsuppressed.
• Assume baseline HIV-positive residents who are unsuppressed at baseline and suppressed at
year 3 are unsuppressed until minimum of 6 months after ART initiation date or year 3.
• Assume baseline HIV-positive residents who are unsuppressed at baseline and unsuppressed at
year 3 are always unsuppressed.
• Among individuals in each of the categories above who are classified as outmigrants at year 3,
censor person-time at date of out-migration.
2. Estimate total unsuppressed time between baseline and year 3 contributed by incident HIV infections
(tested HIV-negative at baseline and HIV-positive at year 3) among baseline residents
• Among incident infections that are unsuppressed at year 3, assume that infection occurred
midway between baseline and year 3, and the individual was never suppressed.
• Among incident infections that are suppressed at year 3, assume that the infection occurred
midway between baseline and ART initiation date, and that the individual was unsuppressed
from time of infection until the minimum of 6 months after ART initiation date or year 3.
• Among individuals in each of the categories above who are classified as outmigrants at year 3,
censor person-time at date of out-migration.
3. Estimate total unsuppressed time between baseline and year 3 contributed by HIV-infected in-
migrants (tested HIV-positive at year 3 and are not baseline enumerated residents).
• Among HIV-positive in-migrants who are unsuppressed at year 3, assume that the individual
was HIV-positive at date of in-migration, and that the individual was never suppressed.
• Among HIV-positive in-migrants who are suppressed at year 3, assume that the individual was
HIV-positive at date of in-migration, and that the individual was unsuppressed from time of
in-migration until the minimum of 6 months after ART initiation date or year 3.
4. Estimate total unsuppressed time between baseline and year 3 contributed by baseline enumerated
residents who are missing baseline HIV status and who are HIV+ at year 3.
• Among individuals who are missing baseline status and tested HIV-positive at year 3 (this
includes both incident infections and baseline prevalent HIV-positive), assume that individual
was baseline prevalent HIV-positive. If suppressed at year 3, assume always suppressed. If
unsuppressed at year 3, assume never suppressed. If classified as out-migrants at year 3, censor
person-time at date of out-migration.
For analyses including the intervention arm only, we will construct analogous estimates of total non-
suppressed time, incorporating all available interim data on migration, HIV status, and HIV RNA levels.
6.1.4 Migration & Mobility
Mobility may impact health outcomes and HIV transmission risk in a number of ways. First, mobile
HIV-positive individuals may be less likely to be diagnosed, treated, and virally suppressed. Thereby,
mobile HIV-positive individuals may be at risk of poor health outcomes and of transmitting HIV. Second,
individuals who migrate into the community during the study will not have benefited from the intervention
prior to moving into the community. Such individuals further are not systematically ascertained during
interim years, and as a result will not be tracked if they do not attend an annual campaign and may fail to
fully benefit from the intervention. Third, individuals who migrate out of the community, as well as those
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who remain official residents but spend substantial time in other locations, may have greater challenges
accessing testing, treatment and care services, while nonetheless continuing sexual contact with community
residents. Finally, mobility may also be associated with additional factors that place individuals at risk of
HIV transmission and acquisition (such as occupations that involve transactional sex). Mobile individuals
may also have more sexual contacts with residents of communities not served by the SEARCH intervention
and thereby sexual contacts who are less likely to be virally suppressed if HIV-positive.
We will, therefore, conduct analyses to quantify migration, to investigate HIV care cascade outcomes
among mobile individuals, and investigate the role mobile individuals play in ongoing transmission. First,
we will report descriptive statistics on the following metrics, stratified by treatment arm, by community,
and within treatment arm by region, sex, and age.
• Baseline mobility: Among baseline adult residents, we will provide descriptive statistics on months
spent outside community in the past year, an indicator of moving main residence within the past
year, and nights spent at the main residence in the past month.
• Follow-up year 3 mobility: Among adult residents at year 3, we will provide descriptive statistics on
time at current residency (less than 1 year, 1-2 years, 2+ years), months spent outside the community
in the past year, an indicator of moving main residence within the past year, nights spent at the main
residence in the past month, indicator of spending more than 6 contiguous months away from main
residence in the last year, an indicator of spending more than 12 contiguous months away outside
of the community in the last 3 years, and an indicator of living in the community for the past 5
years. In this population, we will further report the number and proportion who are classified as
in-migrants, defined as an individual resident in the community at year three, but not at baseline
enumeration. We will provide basic descriptive statistics of the in-migrants’ characteristics (e.g. sex,
age, occupation, relation to head of household), their reason for moving into the household, and their
reported time spent living in the community.
We will also evaluate the following metrics quantifying HIV status and HIV RNA suppression status
among mobile populations.
• HIV prevalence among in-migrants
• The proportion of HIV-positive adult residents at year 3 who are in-migrants
• The proportion of all HIV-positive adult residents with (i) HIV RNA≥500 copies/ml and (ii) HIV
RNA >100,000 copies/ml at year 3 who are in-migrants
• Among HIV-positive adult residents at year 3 who are in-migrants, the proportion with (i) HIV
RNA≥500 copies/ml and (ii) HIV RNA >100,000 copies/ml at year 3
• The proportion of baseline HIV-positive adults who out-migrate by year 3
• Among all adults who are known to be HIV-positive at year 3, are classified as out-migrants, and
have measured HIV RNA, the proportion with (i) HIV RNA<500 copies/ml at year 3, (ii) HIV RNA
>100,000 copies/ml at year 3 - overall and stratified by FUY3 testing location.
6.2 Descriptive and community-level explanatory analyses
The community-specific cumulative incidence (as estimated for the primary outcome) and the community-
specific incidence rates (incident cases per 100 person-years at risk) over the three year period will be
reported. In estimating incidence rates, person-years at risk for individuals who test HIV-negative at both
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baseline and year 3 will be calculated from date of baseline negative test to date of year 3 negative test;
person-years at risk for incident HIV infections will be calculated from date of baseline negative test to
midway between date of baseline HIV-negative test and year 3 HIV-positive test.
We will consider the following independent explanatory variables, estimated as specified in the prior
section:
• HIV prevalence (at baseline and using the average of baseline and year 3).
• HIV RNA metrics: total unsuppressed person-time/total adult person-time; proportion of HIV-
positive adults with HIV RNA> 500 copies/ml and with >100,000 copies/ml, at baseline and using
the average of baseline and year 3; and proportion of total adult population with HIV RNA> 500
copies/ml and with >100,000 copies/ml, at baseline and using the average of baseline and year 3.
• Male circumcision coverage, using the average coverage at baseline and year 3.
• Mobility: proportion of the adult population who are in-migrants at year 3, proportion of the baseline
population who have out-migrated by year 3, proportion of all adults and HIV-positive adults who
are unsuppressed in-migrants.
We will conduct these analyses overall, and stratified by sex. In sex-stratified analyses, we will consider as
additional predictors corresponding to metrics among the opposite sex.
Unadjusted and adjusted associations between each explanatory variable and HIV incidence will be eval-
uated. Community-level Poisson regression of the community-specific HIV incidence on the community-
level explanatory variables, in turn and jointly, will be used to estimate the unadjusted and adjusted
(conditional) relative risks and rates. We will also conduct analyses under the additional assumption
that individual outcomes are independent given the explanatory variables and additional individual-level
covariates included in the adjustment set (listed below). Individual-level Poisson regression will be used
to estimate the relative risk/rate of incident HIV infection per unit change in each explanatory variable,
adjusted for the remaining explanatory variables, region, and additional individual-level risk factors mea-
sured at study baseline (listed below). Inference will employ robust standard error estimates based on an
exchangeable working covariance matrix. In addition to the explanatory variables above and region, these
individual-level analyses will adjust for the following baseline individual-level covariates: sex, age, marital
status, education, occupation, household wealth index, mobility, alcohol use, contraceptive use, polygamy,
and self-reported prior HIV testing.
7 Intervention uptake: Testing, HIV care cascade, and population-level
HIV RNA metrics
The study intervention aims to achieve high annual levels of HIV testing coverage, rapidly initiate ART
among all HIV+ individuals, and retain these individuals in care with HIV viral suppression (plasma
HIV RNA<500 copies/ml). The control arm of the study also aims to achieve high levels of HIV testing
coverage at study baseline, and provides a clinical officer to support adherence to ART guidelines, which
evolved over the course of the study. To evaluate intervention uptake in both study arms over time, with
implications for understanding both health of HIV-positive individuals and HIV transmission potential, we
will conduct the following analyses. Throughout, we will define prior HIV diagnosis and ART initiation
(i) using Ministry of Health records only, and (ii) incorporating self-report.
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7.1 Testing uptake in intervention and control arms
We will provide descriptive statistics to characterize testing coverage and other services by treatment
arm, by community, and over time among the open cohort of adult (≥15 years at year t, t ∈ {0, 1, 2, 3})
community residents. Community residence in a given year will be determined by the baseline enumeration
combined with the re-census of the adult population at year 3. An individual will be considered resident in
the community at year t if he or she was resident at baseline and is not known to have died or out-migrated
by year t, or if he or she was not a resident at baseline and is reported to have in-migrated by year t. In
this open cohort of adult residents, we will report for each year t: (i) the proportion of the population with
known HIV status at the close of year t testing, and (ii) the proportion of the population ever tested for
HIV by the close of year t testing. Known HIV status at year t will be defined as either having a prior
HIV diagnosis or having no prior HIV diagnosis and a positive or negative HIV test result at year t testing.
Ever testing for HIV by year t will be defined as having a prior HIV diagnosis or any prior HIV rapid test
result by close of year t testing. Pre-baseline and secondary analyses will also incorporate self-report of
prior HIV testing and self-reported prior test results.
For each year, by arm and by region, we will report the portion of the eligible population (i) attending
the CHC, (ii) seen at tracking, and (iii) contacted at either CHC or tracking. We will further report
the proportion of the eligible population receiving specific screening and testing services. These include
HIV testing (among those not already known to be HIV-positive), plasma HIV RNA level testing (among
HIV-positive individuals), and hypertension and diabetes screening. We will characterize predictors of not
attending the CHC and of not being contacted at either the CHC or tracking. We will also report the
extent and components of community mobilization carried out prior to testing campaigns.
We will describe clinic-specific timing of the uptake of each of the components of streamlined HIV care:
rapid ART start, appointment reminders, viral load counseling, and tiered tracking for missed visits. We
will also provide clinic-specific timing of the implementation of evolving national ART guidelines in the
control arm. Further analyses of linkage, retention, and suppression over time in intervention and control
communities are described in detail below.
7.2 Cross-sectional cascade coverage in open cohort of HIV-positive individuals
At baseline and year 3 (t = {0, 3}), we will estimate the proportion of all HIV+ adults who are previously
diagnosed, the proportion of previously diagnosed adults who have ever initiated treatment, the proportion
of those ever on ART who are currently suppressed, and overall population-level suppression (the proportion
of all HIV+ who are currently suppressed). This analysis will be based on the open cohort of individuals
who are aged ≥15 years and are community residents at t, as defined above. Primary analyses will
include baseline residents (regardless of stability) and in-migrants identified at follow-up year 3; secondary
analyses will restrict to baseline stable residents. We will also report simple descriptive analyses of HIV
status and suppression among non-residents with measured HIV RNA levels. We will use TMLE to
adjust for potentially differential measurement of HIV status and viral loads, using methods detailed in
[35, 36]; unadjusted numbers and proportions will also be reported. We will conduct sensitivity analyses
to incorporate self-report of prior diagnoses and ART use and to adjust for potentially differential measure
of prior diagnoses and ART use.
We will report cascade and suppression estimates by community, by treatment arm, and for the following
strata: region, sex, age (15-24 years; 25+ years), mobility (< 1mo away; ≥1mo away), students, and
fishermen. We will also generate annual estimates in the intervention arm.
We will estimate the effect of the randomized intervention on population-level suppression at year
3 and test the null hypothesis that population-level viral suppression at year 3 is the same between the
intervention and control arms. To test this null hypothesis, we will use methods analogous to those used for
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the primary study endpoint. Specifically, we will estimate a community-specific outcome (population-level
viral suppression at year 3) and then estimate the effect with a community-level TMLE using data-adaptive
selection of adjustment variables from a pre-specified set. For this outcome, the pre-specified candidate
adjustment variables are the proportion of the baseline HIV-positive population with HIV RNA< 500
copies/ml, and the proportion of baseline HIV-positive adult population below the age of 25. Our primary
analysis will give equal weight to individuals (weight communities relative to the size of their HIV-positive
population); secondary analysis will give equal weight to communities. Subgroup analyses will include
region (using an unadjusted stage II estimator), sex, age, mobility, and circumcision status.
Within each treatment arm, we will also estimate the change in population-level suppression between
baseline and year 3 and test the null hypothesis that population-level viral suppression remained constant
between baseline and year 3. First, we will estimate change in population-level suppression between
baseline and year 3, adjusting for missing HIV serostatus and HIV RNA measures, but without adjusting
for changes in the HIV-positive population over time. This estimate will be based on a comparison of
the time point-specific TMLE-based population suppression estimates described above. Second, we will
estimate the change in population-level suppression over time adjusted for any changes in the distribution
of individual-level characteristics among those with known HIV and viral suppression status over time.
This parameter, in addition to accounting for changes in measurement patterns, adjusts for any changes
in the distribution of the HIV-positive population over time. Estimation will be based on a TMLE that
pools over individuals and years, with time as the exposure of interest. Standard errors will be estimated
based on the estimated influence curve, treating the individuals as independent within communities. In
both approaches, community will be adjusted for as a fixed effect. Outcome and propensity score models
will be fit data-adaptively using Super Learning. Adjustment variables will include age, sex, occupation,
education, mobility, wealth, marital status, and testing location.
For the same primary and secondary populations, we will use analogous methods to estimate the
proportion of all HIV-positive adults in the following viral load strata at baseline and year 3: <1000 cps/ml,
1000-100,000 cps/ml, and >100,000 cps/ml. We will estimate the effect of the randomized intervention
on (i) the population-level proportion with viral loads >100,000 cps/ml, and (ii) the population-level
proportion with viral loads ≥1000 cps/ml. Using methods analogous to those used for suppression, we will
estimate the ratio of the mean of these community-level outcomes between treatment and control arms
and the change in their mean between baseline and year 3, and test the corresponding null hypotheses.
7.3 Longitudinal HIV RNA levels in the closed cohort of baseline HIV-positive indi-
viduals
For the subgroup of adult (aged ≥15) baseline residents diagnosed with HIV at or before baseline, we
will estimate the proportion virally suppressed at year 3 by treatment arm. We will censor at death and
out-migration, using TMLE to adjust for potentially non-differential measurement of viral loads and for
censoring, as detailed in [35, 36]; unadjusted proportions will be reported as secondary analyses. The
primary analysis will include all baseline residents; secondary analyses will restrict to baseline stable
residents.
We will report suppression estimates by region, by community, by treatment arm, and for the following
baseline strata: cascade subgroup (no prior HIV care, prior care but no prior ART initiation, prior ART
but not suppressed, and suppressed), CD4+ T cell count (<350 cells/µl, 350-500 cells/µl, >500 cells/µl)
region, sex, age (15-24 years; 25+ years), mobility (< 1mo away; ≥1mo away), students, and fisherman.
Within the intervention arm, we will report analogous estimate for years 1 and 2.
We will estimate the effect of the randomized intervention on the proportion of the baseline HIV-
positive population who are suppressed at year 3 and test the null hypothesis of no difference in proportion
suppressed between intervention and control, using the same approach as for the open cohort of HIV-
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positive adults (Section 7.2).
Using analogous methods, we will estimate the proportion of baseline HIV-positive individuals in the
following viral load strata at year 3: <1000 cps/ml, 1000-100,000 cps/ml, and >100,000 cps/ml. We will
estimate the effect of the randomized intervention on the proportion of baseline HIV-positive individuals
with viral loads >100,000 cps/ml and test the corresponding null hypothesis.
In a complimentary analysis of the closed cohort of baseline HIV-positive individuals, we will report
the probability of being in each of the following mutually exclusive and exhaustive states at baseline and
follow-up year 3: died, migrated out of the community, newly diagnosed, previously diagnosed but never
on ART, had initiated ART but are unsuppressed, and currently suppressed. This analysis will adjust for
informative viral load measurement, using methods described in [35, 36]; unadjusted estimates will also be
reported.
We will evaluate baseline predictors of (i) having a plasma HIV RNA level >500 copies/ml at year 3,
and (ii) having a plasma HIV RNA >100,000 copies/ml at year 3. Specifically, we will report unadjusted
associations and adjusted variable importance measures on the relative scale (statistical analogs of the
causal risk ratio), treating each baseline predictor in turn as the intervention variable, and the remainder
as the adjustment set. Variable importance measures will be estimated with pooled individual-level TMLE,
adjusted for community as a fixed effect, and treating the household as the independent unit for variance
estimation. Using methods described in [35, 36], we will further adjust for potentially informative censoring
and missing viral load measures. Baseline predictors considered will include region, sex, age, marital status,
education, occupation, household wealth index, mobility, alcohol use, and testing location.
7.4 Time to linkage and ART initiation
For the subgroup of adult residents diagnosed with HIV but not yet on ART at baseline, we will conduct
longitudinal analyses to estimate the probability of initiating ART. Specifically, among adult residents
testing HIV-positive at either the baseline CHC or tracking, and not currently in care, we will evaluate the
probability of ART initiation over time. Time-zero will be the date of the baseline campaign or home-based
contact. Primary analysis will right-censor at the time of death, out-migration, or close of community-
specific follow-up year 3 testing. Secondary analyses will (i) not censor at out-migration, and (ii) censor
at out-migration, but treat death before ART initiation as a failure to initiate. The primary analysis will
include all baseline residents; secondary analyses will restrict to baseline stable residents.
In estimating longitudinal probabilities of ART initiation, we will use Kaplan-Meier analyses, and will
plot the corresponding survival curves by treatment arm and by region. Using a two stage approach, we will
estimate the effect of the randomized intervention on probability of initiating ART by 6, 12, and 24 months.
We will test the corresponding null hypotheses of no intervention effect, using a community-level TMLE
analogous to that used to compare viral suppression between arms, weighting individuals equally and as
candidate adjustment variables the proportion of adult residents known to be HIV-positive at baseline but
not yet on ART at baseline who are (i) aged 15-24 years, and (ii) new HIV diagnoses.
We will report estimates by treatment arm, by region, by community, and for the following baseline
strata: no prior HIV care at at baseline, prior HIV care without a record of prior ART at baseline, CD4
count (<350, 350-500, ≥500), sex, age (15-24 years; 25+ years), and baseline mobility (<1mo away; ≥1mo
away). Among individuals who initiate ART in the control communities, we will document reason for ART
start. We will provide descriptive statistics of the following variables at the time of ART initiation: CD4
count, sex, age, occupation, and mobility (< 1mo away; ≥1mo away) by treatment arm and by community.
We will evaluate baseline predictors of not initiating ART within 12 months. Specifically, we will
report unadjusted associations and adjusted variable importance measures on the relative scale (statistical
analogs of the causal risk ratio), treating each baseline predictor in turn as the intervention variable, and the
remainder as the adjustment set. Variable importance measures will be estimated with pooled individual-
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level TMLE, adjusted for community as a fixed effect, and treating the individual as the independent
unit for variance estimation. Baseline predictors considered will include region, sex, age, marital status,
education, occupation, household wealth index, mobility, alcohol use, and testing location, and CD4 count.
7.4.1 Time to Linkage
Time to ART initiation is a function of both time to linkage and time from linkage to ART start, and both
may be differentially impacted by the study intervention. To further disaggregate these steps in the care
cascade, we will conduct analyses analogous to the above, among individuals who are not currently in HIV
care at baseline (either newly diagnosed with HIV at baseline, or previously diagnosed but not currently
in HIV care), using the alternative outcome of linkage to care, defined as the first recorded visit to an HIV
clinic following baseline.
7.5 Retention in HIV Care
Among HIV-positive adult residents who initiate ART during study follow-up (between the start of base-
line community-specific CHC and start of follow-up year 3 community-specific testing), we will conduct
longitudinal analyses to estimate the probability of being retained in HIV care over time. Retention failure
is defined as more than 90 days late to a scheduled 12-month follow-up [37]. Retention failures include
those living in the community but not engaged in care, those who move out of the community without a
documented transfer, and those otherwise lost to follow-up. Time-zero will be the date of ART initiation.
The primary analysis will right-censor at time of death, documented transfer to a non-SEARCH clinic,
or close of community-specific follow-up year 3 testing. Secondary analyses will also censor at date of
outmigration (even if no transfer documented). The primary analysis will include all baseline residents;
secondary analyses will restrict to baseline stable residents.
In estimating longitudinal probabilities of retention over time, we will conduct both unadjusted (Kaplan-
Meier) analyses and corresponding analyses adjusted for potentially informative censoring using TMLE.
We will plot the resulting survival curves by treatment arm and by region. We will estimate the effect of the
randomized intervention on the probability of being retained in care 12 months after ART initiation and
test the corresponding null hypothesis of no intervention effect, using a community-level TMLE analogous
to that used to compare time to ART initiation between arms - weighting individuals equally and with
candidate adjustment variables consisting of the proportion of adults newly diagnosed with HIV at baseline
who are aged <25 years and the proportion of adults newly diagnosed with HIV at baseline who are mobile
(≥1 month of past year spent outside the community).
Any differences observed in retention between treatment arms may be attributable in part to differences
in the population initiating ART (the population of ART initiators evaluated may differ by study arm in
terms of how challenging they are to retain in care). We will, therefore, conduct complimentary analyses
to estimate the probability of having initiated ART and remaining retained in HIV care.This outcome
captures the total intervention effect on both ART start and subsequent retention among starters.
We will report estimates by treatment arm, by region, by community, and for the following strata: no
prior HIV care at baseline, prior HIV care without a record of prior ART at baseline, study year of ART
initiation, CD4 <500 versus ≥500 at time of ART initiation, and ≤30 days versus >30 days between date
of first HIV-positive test during SEARCH follow-up and ART initiation.
We will provide descriptive statistics as well as evaluate unadjusted and adjusted associations between
baseline individual-level characteristics and non-retention. Specifically, we will report unadjusted associ-
ations and adjusted variable importance measures on the relative scale (statistical analogs of the causal
risk ratio), treating each baseline predictor in turn as the intervention variable, and the remainder as
the adjustment set. Variable importance measures will be estimated with pooled individual-level TMLE,
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adjusted for community as a fixed effect, and treating the individual as the independent unit for variance
estimation. Baseline predictors considered will include region, sex, age, marital status, education, occupa-
tion, household wealth index, mobility, alcohol use, testing location, CD4 count at ART start (<500; ≥
500), and time from diagnosis to ART start (≤ 30 days; > 30days).
We will implement analogous analyses to evaluate retention among individuals with a prior history of
ART use at study baseline who have at least one documented clinic visit post-baseline. For this subgroup,
time-zero is the date of first post-baseline clinic visit, and the primary outcome is, as above, retention 12
months after this date.
7.6 Analysis of interim testing
To further understand the impact of annual population-based testing, for communities in the intervention
arm we will report the following descriptive statistics, overall and by region:
• Number of newly diagnosed HIV-positive individuals seen during population-based testing at time
t; their demographics (sex, age (15-24 years; 25+ years), and baseline mobility (< 1mo away; ≥1mo
away)), CD4+ T cell count, HIV RNA level, prior SEARCH testing history, and residence status
(baseline stable resident, baseline non-stable resident, in-migrant, non-resident); and the proportion
of all HIV-positive individuals seen at time t who are newly diagnosed, overall and stratified by prior
HIV testing history.
• Number of previously diagnosed HIV-positive individuals with no history of ART seen during population-
based testing at time t; their demographics (sex, age (15-24 years; 25+ years), and baseline mobility
(< 1mo away; ≥1mo away)), CD4 count, HIV RNA level, prior SEARCH testing history, and res-
idence status (baseline stable resident, baseline non-stable resident, in-migrant, non-resident); and
the proportion of all HIV-positive individuals seen at time t who are previously diagnosed but with
no prior history of ART.
• Among new diagnoses, time to linkage, time to ART initiation, and the proportion suppressed one
(for new diagnoses at year 1 and year 2) and two years following diagnosis (for new diagnoses at
year 1) (Noting that analysis of these outcomes among individuals testing baseline HIV-positive at
baseline are described above).
Analogous analyses will be conducted restricting to incident HIV infections identified at interim cam-
paigns (i.e. restricting new diagnoses to those with a prior negative HIV test). To quantify background
(non-SEARCH) diagnosis and linkage rates, we will further report in both arms the number and propor-
tion of new diagnoses and of incident infections during the three years of study follow-up using the earliest
record of HIV-positive status recorded in Ministry of Health clinical records or linkage to the tuberculosis
registry rather than SEARCH annual population-based testing.
8 Community adult health outcomes
A primary aim of the SEARCH Study is to understand the intervention’s effect on the health of the
overall community as well as the health of people living with HIV. This section describes evaluation of the
adult health outcomes of mortality, tuberculosis (TB), and non-communicable diseases (NCDs), specifically
diabetes (DM) and hypertension (HTN). Descriptive analyses of ART toxicity and resistance are also given.
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8.1 Mortality
The SEARCH intervention may reduce mortality by enabling earlier diagnosis, earlier ART initiation, and
improved ART retention and suppression outcomes among HIV-positive individuals, as well as, to a lesser
degree, reducing exposure to infectious outcomes like TB. In addition, the comprehensive mortality data
collected as part of SEARCH provides an opportunity to accurately quantify overall mortality in this rural
East Africa setting in the context of universal test and treat, as well as community-wide HIV testing and
linkage to care at study baseline (the active control arm of the trial). In this section, we specify analyses
to compare mortality among baseline HIV-positive individuals and among the overall adult population
between intervention and control arms, as well as additional descriptive and explanatory analyses.
8.1.1 Mortality among HIV-positive adults
Mortality among HIV-positive adults will be compared between arms using a two-stage approach analogous
to that employed for the HIV incidence, ART initiation, and plasma HIV RNA suppression outcomes. The
first stage will estimate community-specific mortality risk among adults known to be HIV-positive at or
before study baseline, both overall and restricted to those with no record of ART use prior to baseline.
Kaplan-Meier estimators will be used to estimate post-baseline survival in each community. In primary
analyses, failure will be defined as death due to illness, and follow-up time will be censored at death to
other causes or out-migration from the community; in secondary analyses, failure will be defined as death
due to any cause. Primary analyses will estimate survival among baseline stable adult residents; sensitivity
analyses will include baseline non-stable residents. In the second stage, risk of mortality by three years
(or, if less than three years, by the minimum Phase 1 follow-up time across communities) will be compared
between arms, weighting individuals equally, and with candidate adjustment variables consisting of the
proportions of the analytic population with baseline CD4+ T cell count ≤50 cells/µl and with baseline
CD4+ T cell count ≤350 cells/µl, as well as for analyses of all baseline HIV-positive adults (including
those on ART at baseline) the proportion of the analytic population with baseline plasma HIV RNA level
<500 copies/ml.
To distinguish between the impact of streamlined linkage and ART delivery in the intervention arm
from the impact due to differences in CD4+ T cell count eligibility threshold for ART initiation at study
baseline, we will further conduct subgroup analyses testing the null hypothesis of no difference in mortality
risk between arms within subgroups defined by baseline CD4+ T cell count: ≤350 cells/µl and >350
cells/µl. The intervention effect will be estimated using a two stage approach identical to the primary
analysis described above, with the exception of the following modification to the candidate CD4-based
adjustment variables used in Stage 2:
• For the subgroup of baseline CD4+ T cell count ≤350 cells/µ: the proportion with CD4+ T cell
count ≤100 cells/µl
• For the subgroup of baseline CD4+ T cell count >350 cells/µ: the proportion with CD4+ T cell
count 350-500 cells/µl
We will also report the following descriptive analyses of mortality among baseline HIV-positive indi-
viduals:
• Kaplan-Meier-based survival estimates, stratified by baseline cascade status (no prior HIV care, prior
HIV care but no prior ART, prior ART but with plasma HIV RNA level ≥500 copies/ml at baseline,
and plasma HIV RNA level <500 copies/ml at baseline)
• Estimated mortality rates (per 100,000 person years) with person-time at risk beginning at the start
of Phase I and ending at death, out-migration, or end of phase 1. Mortality rates will be reported
among all baseline HIV-positive individuals, and among baseline HIV-positive adults aged 15-59.
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Primary analyses will be based on baseline stable residents; secondary analyses will include non-stable
residents.
We will further estimate unadjusted and adjusted predictors of death among the baseline HIV-positive
population. A pooled individual-level TMLE including community as a fixed effect will be used to estimate
adjusted and unadjusted variable importance measures (on the relative scale) for the following covariates:
sex, age, marital status (including widow as a separate category if sufficient data support exists), education,
occupation, household wealth index, mobility, having a baseline HIV+ adult (other than the current
individual) in the same household, baseline CD4+ T cell count, and baseline plasma HIV RNA level <500
copies/ml.
Finally, we will estimate the mortality rate due to illness, and due to any cause, following ART initiation.
Person-time at risk will begin at the time of ART initiation and end at the first of death, out-migration or
end of Phase 1. We will compare this rate between arms, using a two stage TMLE, weighting person-time
equally and with candidate adjustment variables consisting of the proportions of baseline HIV-positive
individuals not on ART at baseline with CD4+ T cell count ≤50 cells/µl and CD4+ T cell count ≤350
cells/µl at baseline. In interpreting this cross arm comparison, we note that any difference between arms
will be a function of both any intervention effect on the underlying mortality risk of individuals initiating
ART (i.e. via intervention effects on time to ART initiation overall and within subgroups), as well as any
effect of the intervention on survival post-ART initiation. In descriptive analyses, Kaplan-Meier-based
survival following ART initiation will also be estimated.
8.1.2 Mortality among all adults
Mortality rate (all-cause, and due to illness) will be estimated among all baseline stable residents (primary)
and among all baseline residents (regardless of stability; secondary). Person-time at risk will begin at the
first of the start of Phase 1, or age ≥15 years, and will end at the first of death, out-migration, or the
end of Phase 1. We will compare this rate between arms, using a two stage TMLE weighting person-time
equally, with candidate adjustment variables consisting of baseline HIV prevalence and the proportion of
adult residents falling in lowest quintile of household socioeconomic index.
Additional descriptive analyses of mortality in the adult population will include:
• A description of the distribution of causes of death (illness, childbirth, homicide, accident, suicide)
among adult deaths, stratified by arm.
• Age-adjusted mortality rates, using direct standardization to the WHO standard age distribution,
and stratified by arm and by baseline HIV status.
• Unadjusted and adjusted predictors of mortality, analogous to the variable importance measures
estimated for the baseline HIV-positive population.
8.1.3 Comparison of mortality between HIV-positive and HIV-negative adults
We will compare mortality rates between the adult baseline HIV-positive and baseline HIV-negative popu-
lations, over all communities, and stratified by region and treatment arm. Mortality rates will be standard-
ized to the pooled age-sex distribution of the populations being compared. We will compare survival curves
over time between the adult baseline HIV-positive and HIV-negative populations, using both unadjusted
Kaplan-Meier estimators, and TMLE of baseline HIV-status-specific survival curves, adjusted for baseline
predictors of mortality including age, and including community as a fixed effect.
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8.2 Tuberculosis (TB)
More rapid initiation and effective ART delivery as a result of streamlined care may reduce the incidence
of TB disease and death among HIV-positive individuals by reducing susceptibility to TB disease among
HIV-positive persons, and by reducing death due to HIV-associated TB. In this section we describe analyses
to compare the composite outcome of HIV-TB and death between treatment arms, as well as additional
descriptive analyses of incident active TB and TB-associated morbidity.
8.2.1 Incident Active HIV-associated Tuberculosis
Our primary HIV-TB outcome for comparison between intervention and control arms will be estimated
among baseline stable adult residents who either test HIV-positive at baseline or who have a missing
baseline HIV test. Our motivation for including individuals with a missing baseline HIV test is that
individuals who are harder to access for HIV testing may be those individuals at higher risk of HIV-TB.
In sensitivity analyses we will (i) include non-stable residents; and (ii) restrict to individuals known to be
HIV-positive at baseline. The population will exclude individuals with an active TB diagnosis within 6
months prior to the start of Phase 1. In this population, we will estimate risk of the composite outcome of
(i) death due to illness or (ii) incident active TB disease with an HIV diagnosis recorded at or prior to date
of TB diagnosis. The primary HIV-TB analysis is focused on this composite outcome based on evidence
that a substantial portion of death due to illness among HIV-positive persons is due to undiagnosed TB.
Comparison of HIV-TB outcomes between arms will be based on a two stage analysis. In the first stage,
community-specific Kaplan-Meier estimators will be used to estimate the risk of the composite outcome
by three years (or the minimal time for which all communities have follow-up), censoring at death due to
other causes or out-migration. In the second stage, these community-level risk estimates will be compared
between arms using TMLE, weighting individuals equally, and with a candidate adjustment set consisting
of (i) baseline HIV prevalence among adults, and (ii) the number of TB cases diagnosed in year prior to
baseline divided by the number of baseline adult residents.
In secondary analyses, we will evaluate the non-composite outcome of HIV-associated TB (censoring
at outmigration or death due to any cause) among the full adult population (irrespective of baseline HIV
status). Comparison of these secondary outcomes between arms will be implemented analogously to the
primary TB outcome, using community-specific Kaplan Meier estimators to estimate risks, and comparing
estimated risks between arms using TMLE, weighting individuals equally, and with the same candidate
adjustment set as for the primary TB outcome.
The above analyses will also be implemented stratifying on region (unadjusted Stage 2 estimator only)
and for the following subgroups: (i) baseline HIV-positive adults with baseline CD4+ T cell count ≤500
cells/µl; (ii) baseline HIV-positive adults with baseline CD4+ T cell count >500 cells/µl; (iii) baseline
HIV-positive adults with baseline plasma HIV RNA level ≥500 copies/ml; and (iv) men and women.
8.2.2 Additional TB analyses
We will implement the following additional secondary analyses to characterize incident active TB by HIV
status, to determine the predictors of HIV-associated active TB, and to compare the clinical outcomes of
participants with active TB in intervention vs. control communities. The overall goal of these secondary
analyses is to better understand potential changes in the epidemiology of HIV-associated TB, including
how the SEARCH intervention might impact the risk of developing active TB and clinical outcomes.
• We will report Kaplan-Meier survival curves for the time-to-event outcomes corresponding to the
primary and secondary HIV-TB outcomes, by region and arm, and within the following subgroups:
baseline HIV-positive adults with CD4+ T cell count ≤500 and >500 cells/µl at baseline; baseline
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HIV-positive adults with plasma HIV RNA level ≥500 and <500 copies/ml at baseline; men and
women; youth (aged 15-24 years) and older individuals (aged ≥ 25 years).
• We will use Kaplan-Meier estimators to evaluate the risk over time for developing (i) TB, and (ii) HIV-
TB among (i) the baseline HIV-negative population, and (ii) the baseline HIV-positive population,
censoring at death or outmigration. We will report the corresponding survival curves.
• We will estimate annualized TB and HIV-TB incidence rates in an open cohort of adult residents,
overall and stratified by baseline HIV status. Person-time at risk will begin at the first date at
which the individual is a community resident (either a baseline resident, or has in-migrated, using
in-migration date ascertained at year 3) and aged ≥15 years, and will end at the first of diagnosis of
active TB, death, outmigration, or end of Phase 1. Annual TB incidence rates will be reported by
community and by treatment arm (overall and within region).
8.2.3 Predictors of incident TB
We will report unadjusted associations and adjusted variable importance measures on the relative scale
(statistical analogs of the causal risk ratio), treating each baseline predictor in turn as the intervention
variable, and the remainder as the adjustment set. Variable importance measures will be estimated with
pooled individual-level TMLE, using the community as the independent unit when estimating variance,
and with inference based on the t-distribution. The population, outcome, and right-censoring variables will
be defined as for the primary outcome; analogous to predictors of HIV seroconversion, secondary analysis
will consider community as a fixed effect. Baseline predictors considered will include: sex, age, education,
household wealth, mobility, alcohol use, and among baseline HIV+, baseline CD4+ T cell count and plasma
HIV RNA level. Predictors will be evaluated overall and stratified by baseline HIV status.
8.2.4 Characterization of active TB cases by HIV status
We will conduct the following analyses to evaluate how individuals diagnosed with active TB and the clinical
presentation of active TB varies over time and by HIV status. Specifically, we will describe demographic
and clinical characteristics of incident active TB cases diagnosed during Phase 1, overall and stratified
by (i) HIV status, (ii) intervention vs. control arm, and (iii) by study year. We will provide descriptive
statistics of the following characteristics of TB cases: demographics (age, sex, wealth index, education);
mobility; TB disease site (pulmonary, extra-pulmonary); AFB smear; TB disease type (new, re-treatment,
failure, default); and, among HIV-positive individuals, CD4+ T cell count and plasma HIV RNA level at
time of TB treatment start.
We will also calculate the empirical proportion of incident TB cases that are HIV-associated (defined,
as for the primary outcome, as having an HIV diagnosis at or prior to TB diagnosis date), stratified by
intervention arm and by year. We will compare this proportion between intervention and control arms
using the two stage approach used for the primary TB outcome.
8.2.5 Clinical Outcomes among HIV-associated TB cases
We hypothesize that TB clinical outcomes following TB treatment start will be positively impacted by the
SEARCH intervention due to earlier diagnosis of HIV, universal access to ART, and streamlined HIV care
delivery. These impacts may include reduced mortality during TB treatment, reduced risk of IRIS (defined
as CD4<100 at TB treatment start), and more rapid time to ART start (if not on ART at TB diagnosis)
in intervention communities compared to control.
Among individuals diagnosed with HIV-associated, incident active TB disease in Phase 1, we will
estimate the mortality rate due to illness during TB treatment, with person-time at risk beginning on date
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of TB treatment initiation and ending on first of out-migration, death due to other causes, TB treatment
end date, or end of Phase 1. We will compare this rate between intervention arms with a two-stage
approach analogous to the approach used for the primary TB outcome, weighting person-time equally,
and with candidate adjustment variables consisting of proportion of baseline HIV-positive individuals with
CD4+ T cell count≤350 cells/µl, and proportion of baseline HIV-positive individuals with HIV RNA level
<500 copies/ml. As with mortality rates following ART initiation, we note any intervention effect may
be mediated in part by impacts on the characteristics of TB treatment initiators at time of TB treatment
start.
We will also report the following descriptive analyses:
• The proportion of incident active TB cases among HIV-positive individuals with CD4+ T cell count
<200 cells/µl that develop IRIS
• The proportion of incident active TB cases with prior ART use at time of TB diagnosis
• Time to ART initiation following incident active TB diagnosis among individuals who are HIV-
positive and not on ART at the time of TB diagnosis
8.3 Non-Communicable Diseases
At baseline, all communities received population-based hypertension (HT) screening and referral for treat-
ment according to national guidelines. Intervention communities further received annual population-based
HT screening, with HT treatment for HIV-positive and HIV-negative individuals delivered using an inte-
grated streamlined-care delivery model. Screening and care for diabetes (DM) was delivered analogously
in the intervention and control arms, with the exception that DM screening at baseline was limited to
Ugandan communities. The SEARCH intervention may thus improve HT and DM control through earlier
diagnosis and through more effective treatment delivery. As with HIV RNA suppression and HIV incidence,
baseline population-based testing in the control arm may also improve HT/DM control over time. In this
section, we describe analyses to evaluate these hypotheses among adults aged ≥ 30 years at follow-up year
3. As throughout, to ensure comparable data structures, analyses comparing intervention and control arms
only make use of data collected at population-based testing at baseline and at follow-up year 3.
We define HT control as having at least one systolic blood pressure (BP) measurement <140 mmHg
and at least one diastolic BP measurement <90 mmHg. In other words, uncontrolled HT is defined as
all systolic BP measures ≥140 mmHg or all diastolic BP measures ≥ 90 mmHg (requiring that at least
one BP measure was recorded). We define prevalent HT as current or previous (i) self-report of a prior
diagnosis, or (ii) uncontrolled blood pressure. For HIV-positive and HTN prevalent persons, dual-control is
defined as joint control of HT and suppressed viral replication (<500 copies/ml). The metrics for DM are
defined analogously, with DM control defined as a finger-prick blood glucose ≤11 mmol/L and prevalent
DM defined as previous or current (i) self-report of a prior diagnosis, or (ii) uncontrolled blood glucose.
8.3.1 Hypertension (HT) control among individuals with prevalent HT at year 3
HT control among adults aged ≥ 30 years and with prevalent HT at year 3 will be compared between
arms using the two-stage approach, detailed above. The first stage will estimate the community-specific
proportion of adults with prevalent HT at year 3 who have their HT controlled at follow-up year 3, both
overall and among those known to be HIV-positive at year 3. Using an approach analogous to that used to
estimate population-level viral suppression, these population-level proportions will be estimated for each
community using an individual-level TMLE, adjusting for incomplete measures of both HT disease status at
year 3 and incomplete measures of disease control at year 3. Secondary analyses will restrict to individuals
known to have HT at year 3, adjusting for incomplete measures of disease control. Among adults with
prevalent HT and HIV at year 3, we will also estimate the community-specific proportion with dual-control
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(both controlled HT and plasma HIV RNA level <500 copies/ml) at follow-up year 3, adjusting for missing
measures of both HT control and plasma HIV RNA at year 3.
Primary analyses will be restricted to baseline stable residents; sensitivity analyses will include baseline
non-stable residents and in-migrants identified in year 3 testing. Primary analyses will condition on being
alive and resident in the community at follow-up year 3; secondary analyses will further adjust for censoring
by death and out-migration. Sensitivity analyses will be based on unadjusted empirical proportions.
In the second stage, community-specific estimates of control at follow-up year 3 will be compared
between arms, weighting individuals equally, and with the following candidate adjustment variables:
• baseline CHC testing coverage and baseline prevalence of having a body mass index (BMI) > 24
when estimating the effect on HT control at follow-up year 3
• baseline CHC testing coverage and baseline dual-control when estimating the effect on dual-control
at follow-up year 3
We will also test the null hypothesis of no intervention effect stratifying on region (for each population) in
unadjusted analyses. Using the analogous two-stage approach, we will also report estimates of HT control
and HIV-HT dual-control stratified by community, by intervention arm, and within intervention by region,
sex, and age (30-44 years, 45-59 years, 60+ years).
8.3.2 HT control among individuals with prevalent HT at baseline
HT control among adults (≥30 years) known to have HT at baseline (via self-report or elevated blood
pressure at baseline) will be compared between arms using the two-stage approach, detailed above. The
first stage will estimate the community-specific proportions of adults known to have HT at baseline who
have their HT controlled at follow-up year 3, overall and among those also known to be HIV-positive
at baseline (with and without a further restriction on uncontrolled viral replication at baseline). For
the baseline HIV-HT prevalent population, we will also estimate the community-specific proportions with
dual-control at follow-up year 3. These proportions will be estimated with TMLE, adjusting for incomplete
measures of control at year 3 (including HIV RNA levels for the dual-control outcome); secondary analyses
will be unadjusted. Primary analyses will be restricted to baseline stable residents; sensitivity analyses
will include baseline non-stable residents. Primary analyses will condition on being alive and resident
in the community at follow-up year 3; secondary analyses will further adjust for censoring by death and
out-migration.
In the second stage, estimates of control at follow-up year 3 will be compared between arms, weighting
individuals equally, and with candidate adjustment variables:
• baseline CHC testing coverage and baseline control when estimating the effect on HT control at
follow-up year 3
• baseline CHC testing coverage and baseline dual-control when estimating the effect on dual-control
at follow-up year 3
We will also test the null hypothesis of no intervention effect stratifying on region (for each population)
in unadjusted analyses. We will report estimates of HT control and HT-HIV dual-control stratified by
community, by intervention arm, and within intervention by region, sex, and age (30-44 years, 45-59 years,
60+ years).
8.3.3 Predictors of uncontrolled HT
We will conduct the following analyses to evaluate individual-level predictors of uncontrolled HT at follow-
up year 3. We will report unadjusted associations and adjusted variable importance measures on the relative
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scale (statistical analogs of the causal risk ratio), treating each baseline predictor in turn as the intervention
variable, and the remainder as the adjustment set. Variable importance measures will be estimated with
a pooled individual-level TMLE, adjusted for community as a fixed effect and adjusting for potentially
differential missingness of HT control measures. These descriptive statistics and predictor analyses will
be reported for the following populations: all adults, HT-prevalent at follow-up year 3, HIV-positive at
follow-up year 3, and HIV-HT prevalent at follow-up year 3. For the HIV-HT prevalent population, we will
also evaluate predictors of lack of dual-control. Baseline predictors considered will include region, sex, age
(30-44 years, 45-49 years, and 60+ years), marital status, education, occupation, household wealth index,
mobility, alcohol use, and body mass index (BMI). Additional predictors for HIV-positive populations
include evidence of prior HIV diagnosis and previous treatment with ART.
8.3.4 NCD (hypertension and diabetes) control and predictors of uncontrolled NCD
We will conduct the following analyses to examine the intervention impact on both HT and diabetes (DM)
control, as well as predictors of uncontrolled NCD at follow-up year 3. We consider an individual to be
NCD prevalent if he or she is HT prevalent and/or DM prevalent at a given time-point. NCD control is
defined as current control of all prevalent NCDs. Dual HIV-NCD control is defined as current control of
all of prevalent NCDs and plasma HIV RNA level <500 copies/ml.
The analyses described in Sections 8.3.1 and 8.3.2 will be repeated to estimate NCD control and dual
HIV-NCD control at follow-up year 3. Specifically, we will estimate the intervention effect on
• NCD control at follow-up year 3 in the overall population of adults with prevalent NCD at follow-up
year 3, in the population of adults who are HIV-NCD prevalent at follow-up year 3, and in the
subgroups specified above
• Dual HIV-NCD control at follow-up year 3 in the population of adults who are HIV-NCD prevalent
at follow-up year 3, and within the subgroups specified above
• NCD control at follow-up year 3 in the overall population of Ugandan adults with prevalent NCD at
baseline, in the population of Ugandan adults who are HIV-NCD prevalent at baseline, and within
the subgroups specified above
• Dual HIV-NCD control at follow-up year 3 in the population of Ugandan adults who are HIV-NCD
prevalent at baseline and within the subgroups specified above
(Recall screening for DM occurred only in Uganda communities at baseline.) We will also conduct a
sensitivity analysis where all individuals are considered to have blood glucose ≤11 mmol/L unless there is
evidence otherwise.
The analyses specified in Section 8.3.3 will be repeated to evaluate predictors of uncontrolled NCD at
follow-up year 3.
8.3.5 HT and NCD care cascades
Analogously to the HIV care cascade (Section 7.2), we will estimate the following population-level metrics
at baseline and year 3 (t = {0, 3}): prevalence among adult residents (aged ≥ 30 years), the proportion
of all prevalent adults who are previously diagnosed, the proportion of previously diagnosed who have
ever initiated treatment, the proportion of treatment initiators who are currently controlled, and the
overall population-level control (the proportion of all prevalent adults who are currently controlled). These
analyses will be performed for the overall population as well as the HIV-positive population at time t.
Primary analyses will use TMLE to adjust for potentially differential measurement of both disease
status and control; unadjusted numbers and proportions will also be reported. Primary analyses will
include baseline residents (regardless of stability) and in-migrants identified at follow-up year 3; secondary
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analyses will restrict to baseline stable residents. Primary analyses will condition on being alive and
resident in the community at time t; secondary analyses will further adjust for censoring by death and
out-migration. For both HT (only) and NCD (HT and/or DM), these metrics will be estimated overall,
and stratified by community, by intervention arm, and within intervention by region, sex, and age (30-44
years, 45-59 years, 60+ years). We will generate analogous estimates of dual-control for the HIV-NCD
prevalent population. Annual estimates of cascade coverage will also be reported in the intervention arm.
To further understand the impact of the intervention on the HTN and the NCD care cascades, we will
conduct the following analyses.
• Using analogous methods to those described in Section 7.2, we will estimate in each arm the change
in cascade coverage from baseline to follow-up year 3.
• Using analogous methods to those described in Section 7.3, we will estimate HT and NCD care
cascade outcomes at year 3 in a longitudinal closed cohort of adults with baseline prevalent disease
(overall and among baseline HIV-positive). We will characterize this cohort by baseline status (prior
diagnosis, treatment and control) as well as evaluate individual-level risk factors for lack of control
at follow-up year 3. Within the intervention arm, we will report analogous estimates for years 1 and
2.
8.4 Antiretroviral Treatment Associated Toxicities
We will report number and incidence of grade 3 and grade 4 adverse events and treatment limiting toxicity
among individuals initiated on ART outside country guidelines.
8.5 Antiretroviral resistance among HIV-positive individuals
Drug resistance among HIV-infected individuals will be assessed based on the presence of NRTI, PI, and
NNRTI mutations. Transmitted resistance will be assessed at year 3 based on the prevalence of resistance
mutations at year 3 among individuals with HIV-seroconversion during the course of the study who remain
ART na¨ıve at year 3. Transmitted resistance at time of first HIV diagnosis will also be reported among
interim seroconversions in the intervention arm of the study. Acquired resistance will be assessed at
baseline and year 3 based on the prevalence of resistance mutations among HIV-positive individuals with
a history of prior ART initiation, stratified by current ART use at baseline and year 3. Resistance will be
reported stratified by community, treatment arm, and within treatment arm by region. The demographic
characteristics (sex, age (15-24 years; 25+ years), and baseline mobility (< 1mo away; ≥1mo away)) of
individuals with resistance will be summarized.
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